Ultragenyx Pharma (RARE) Reports Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy
Go back to Ultragenyx Pharma (RARE) Reports Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.65 +0.14 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.51 | 52 Week High | $117.12 | |||
| Open | $14.58 | 52 Week Low | $46.52 | |||
| Day High | $15.01 | P/E | N/A | |||
| Day Low | $14.28 | EPS | $-1.97 | |||
| Volume | 5,270,161 | |||||
